立体定向放疗治疗周围型非小细胞肺癌

doi:10.3760/cma.j.issn.1673-422X.2013.12.012

摘要/Abstract

摘要： 立体定向放疗（SBRT）可对病变实施“手术”式照射，抑制肿瘤细胞增殖，并具有非侵入性的特点，能明显缩短治疗时间。尽管手术、放疗是早期周围型非小细胞肺癌的主要选择，但近来研究表明SBRT相对普通放疗在局部控制率、不良反应等方面具有一定优势，并可获得与手术治疗相近的疗效。

关键词: 癌, 非小细胞肺, 放射外科手术, 治疗结果

Abstract: Stereotactic body radiotherapy (SBRT) can treat the lesions in a "surgical" manner and inhibit tumor cell proliferation. Furthermore, it has a character of "noninvasive", which shortens the duration of treatment. Although surgery and radiotherapy are the major means for early stage peripheral nonsmall cell lung cancer, some studies in recent years show that SBRT has certain advantages in local control ratio and adverse reaction compared with radiotherapy, and acquires the similar curative effect with surgery.

Key words: Carcinoma, nonsmallcell lung, Radiosurgery, Treatment outcome

王伟林, 杜泽东, 李昌林. 立体定向放疗治疗周围型非小细胞肺癌[J]. 国际肿瘤学杂志, 2013, 40(12): 918-920.

WANG Wei-Lin, DU Ze-Dong, LI Chang-Lin. Stereotactic body radiotherapy for peripheral nonsmall cell lung cancer[J]. Journal of International Oncology, 2013, 40(12): 918-920.

参考文献

［1］ van Baardwijk A, Tomé WA, van Elmpt W, et al. Is highdose stereotactic body radiotherapy (SBRT) for stage Ⅰ nonsmall cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol, 2012, 105(2): 145149. ［2］ Louie A, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable Stage Ⅰ nonsmallcell lung cancer: a Markov modelbased decision analysis. Int J Radiat Oncol Biol Phys, 2011, 81(4): 964973. ［3］ Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage ⅠⅡ nonsmallcell lung cancer. Int J Radiat Oncol Biol Phys, 2009, 73(4): 12351242. ［4］ VanderWalde A, Pal S, Reckamp K， et al. Management of nonsmallcell lung cancer in the older adult. Maturitas, 2011, 68(4): 311321. ［5］ Bral S, Gevaert T, Linthout N, et al. Prospective, riskadapted strategy of stereotactic body radiotherapy for earlystage nonsmallcell lung cancer: results of a Phase Ⅱ trial. Int J Radiat Oncol Biol Phys, 2011, 80(5): 13431349. ［6］ Chen Y, Guo W, Lu Y, et al. Doseindividualized stereotactic body radiotherapy for T13N0 nonsmall cell lung cancer: longterm results and efficacy of adjuvant chemotherapy. Radiother Oncol, 2008, 88(3): 351358. ［7］ Feddock J, Arnold S, Shelton B, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced nonsmall cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys, 2013, 85(5): 13251331. ［8］ Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of Stage Ⅰnonsmallcell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys, 2012, 82(3): 11491156. ［9］ Louie A, Rodrigues G, Hannouf M, et al. Withholding stereotactic radiotherapy in elderly patients with stage Ⅰ nonsmall cell lung cancer and coexisting COPD is not justified: outcomes of a Markov model analysis. Radiother Oncol, 2011, 99(2): 161165. ［10］ Palma D, Visser O, Lagerwaard F， et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage Ⅰ nonsmallcell lung cancer: a populationbased timetrend analysis. J Clin Oncol, 2010, 28(35): 51535159. ［11］ Iwata H, Demizu Y, Fujii O, et al. Longterm outcome of proton therapy and carbonion therapy for large (T2aT2bN0M0) nonsmallcell lung cancer. J Thorac Oncol, 2013, 8(6): 726735. ［12］ Bishawi M, Kim B, Moore W, et al. Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys, 2012, 82(1): e107110. ［13］ Takeda A, Enomoto T, Sanuki N, et al. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest, 2013, 143(1): 130137. ［14］ Ohri N, WernerWasik M, Grills IS, et al. Modeling local control after hypofractionated stereotactic body radiation therapy for stage Ⅰ nonsmall cell lung cancer: a report from the elekta collaborative lung research group. Int J Radiat Oncol Biol Phys, 2012, 84(3): e379384. ［15］ Daly M, Perks J, Chen A. Patternsofcare for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol, 2013, 8(2): 202207. ［16］ Olsen JR, Robinson CG, El Naqa I, et al. Doseresponse for stereotactic body radiotherapy in earlystage nonsmallcell lung cancer. Int J Radiat Oncol Biol Phys, 2011, 81(4): e299303. ［17］ Guckenberger M, Allguer M, Appold S， et al. Safety and efficacy of etereotactic body radiotherapy for stage Ⅰ nonsmallcell lung cancer in routine clinical practice: a patternsofcare and outcome analysis. J Thorac Oncol, 2013, 8(8): 10501058. ［18］ Ge H, Cai J, Kelsey C, et al. Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer. Int J Radiat Oncol Biol Phys, 2013, 85(2): 438443. ［19］ Mancosu P, Sghedoni R, Bettinardi V, et al. Semiautomatic technique for defining the internal gross tumor volume of lung tumors close to liver/spleen cupola by 4DCT. Med Phys, 2010, 37(9): 45724576. ［20］ Chi A, Liao Z, Nguyen N, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage nonsmallcell lung cancer: clinical implications. Radiother Oncol, 2010, 94(1): 111. ［21］ Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA, 2010, 303(11): 10701076. ［22］ Senthi S, Lagerwaard F, Haasbeek C, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage nonsmallcell lung cancer: a retrospective analysis. Lancet Oncol, 2012, 13(8): 802809.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.